Exact Sciences Corporation (EXAS): Price and Financial Metrics
Exact Sciences Corporation (EXAS)
Today's Latest Price: $150.00 USD
Updated Jan 22 4:00pm
Add EXAS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
EXAS Stock Summary
- With a market capitalization of $22,563,605,250, Exact Sciences Corp has a greater market value than 89.91% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Exact Sciences Corp is reporting a growth rate of 179.92%; that's higher than 92.29% of US stocks.
- Revenue growth over the past 12 months for Exact Sciences Corp comes in at 82.48%, a number that bests 93.57% of the US stocks we're tracking.
- Stocks that are quantitatively similar to EXAS, based on their financial statements, market capitalization, and price volatility, are AKAM, WST, LOGI, HZNP, and NDAQ.
- EXAS's SEC filings can be seen here. And to visit Exact Sciences Corp's official web site, go to www.exactsciences.com.
EXAS Stock Price Chart Interactive Chart >
EXAS Price/Volume Stats
| Current price | $150.00 | 52-week high | $152.87 |
| Prev. close | $148.07 | 52-week low | $35.25 |
| Day low | $146.20 | Volume | 1,370,000 |
| Day high | $150.32 | Avg. volume | 1,906,864 |
| 50-day MA | $131.19 | Dividend yield | N/A |
| 200-day MA | $99.88 | Market Cap | 22.56B |
Exact Sciences Corporation (EXAS) Company Bio
Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.
Loading social stream, please wait...